Global Radionuclide Drug Conjugates (RDC) Supply, Demand and Key Producers, 2023-2029

Global Radionuclide Drug Conjugates (RDC) Supply, Demand and Key Producers, 2023-2029

The global Radionuclide Drug Conjugates (RDC) market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

RDC therapy combines radionuclides with specific monoclonal antibodies to achieve the dual advantages of precise targeting and powerful killing of tumor cells. It can highly concentrate the energy released by radionuclides within several times the diameter of cancer cells, thereby minimizing damage to surrounding normal tissues. This enables it to effectively kill cancer cells while protecting normal tissues, so it has good curative effect and low adverse reactions, and can prolong the survival of patients with advanced cancer, which is of great significance to the treatment of advanced tumors.

According to the function, RDC can be divided into RDC for diagnosis and RDC for treatment, and the functional classification is closely related to the type of nuclide.

At present, the most widely used nuclide for diagnosis is 99mTc, and the nuclide for treatment is 131I, 90Y and 223Ra. Radionuclide technology provides unique advantages for early diagnosis and targeted therapy of tumors, but the acquisition and preparation technology of radionuclide still limits its wider clinical application and needs further research and development.

According to different targeting ligands, RDC can be subdivided into: antibody-conjugated nuclide drugs (ARC) and small molecule-conjugated nuclide drugs (including polypeptide-conjugated nuclide drugs-PRC).

According to the data of the Global New Drug Information Database, among the RDC drugs currently in clinical research and on the market, the main research targets are CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), SSTR (somatostatin receptor ); the main indications are concentrated in neuroendocrine tumors, prostate cancer, and renal cell carcinoma.

This report studies the global Radionuclide Drug Conjugates (RDC) demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Radionuclide Drug Conjugates (RDC), and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Radionuclide Drug Conjugates (RDC) that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Radionuclide Drug Conjugates (RDC) total market, 2018-2029, (USD Million)

Global Radionuclide Drug Conjugates (RDC) total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Radionuclide Drug Conjugates (RDC) total market, key domestic companies and share, (USD Million)

Global Radionuclide Drug Conjugates (RDC) revenue by player and market share 2018-2023, (USD Million)

Global Radionuclide Drug Conjugates (RDC) total market by Type, CAGR, 2018-2029, (USD Million)

Global Radionuclide Drug Conjugates (RDC) total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Radionuclide Drug Conjugates (RDC) market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Uihc Pet Imaging and Grand Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Radionuclide Drug Conjugates (RDC) market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Radionuclide Drug Conjugates (RDC) Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Radionuclide Drug Conjugates (RDC) Market, Segmentation by Type
Antibody Radionuclide Conjugates (ARC)
Peptide Radionuclide Conjugates (PRC)
Small Molecular Radionuclide Conjugates (SMRC)

Global Radionuclide Drug Conjugates (RDC) Market, Segmentation by Application
Neuroendocrine Tumors
Prostate Cancer
Renal Cell Carcinoma

Companies Profiled:
POINT Biopharma
Telix
ITM AG
Bayer AG
Novartis
Lantheus
Curium Pharma
Uihc Pet Imaging
Grand Pharma
BoomRay Pharmaceuticals
SmartNuclide Biopharma
Hengrui Medicine
Yunnan Baiyao Group
Sinotau
Hexin Pharmaceutical
Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.

Key Questions Answered

1. How big is the global Radionuclide Drug Conjugates (RDC) market?

2. What is the demand of the global Radionuclide Drug Conjugates (RDC) market?

3. What is the year over year growth of the global Radionuclide Drug Conjugates (RDC) market?

4. What is the total value of the global Radionuclide Drug Conjugates (RDC) market?

5. Who are the major players in the global Radionuclide Drug Conjugates (RDC) market?

6. What are the growth factors driving the market demand?